DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2022
US$ 3,000.00
... and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2019 The ...
March 2022
100 pages
Myasthenia Gravis - Pipeline Insight, 2022
US$ 2,000.00
... clients within 48 Hours 'Myasthenia Gravis - Pipeline Insight, 2019' report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Myasthenia Gravis development. The report provides ...
March 2022
60 pages
Asthma - Pipeline Insight, 2022
US$ 3,000.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “Asthma - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in...
March 2022
100 pages
Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 25...
March 2022
60 pages
Cystic Fibrosis - Pipeline Insight, 2022
US$ 3,000.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “Cystic Fibrosis - Pipeline Insight, 2022,” report provides comprehensive insights about 75+ companies and 80+ pipeline dr...
March 2022
100 pages
Dravet Syndrome - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Dravet Syndrome - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline...
March 2022
50 pages
RIPK1 inhibitor - Pipeline Insights, 2022
US$ 1,500.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “RIPK1 inhibitors – Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 12+ pipeline d...
March 2022
50 pages
Glioblastoma - Pipeline Insight, 2022
US$ 3,000.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “Glioblastoma - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline dru...
March 2022
100 pages
AXL kinase inhibitors - Pipeline Insights, 2022
US$ 2,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “AXL kinase inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pi...
March 2022
60 pages
Herpes Zoster - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Herpes Zoster – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline d...
March 2022
50 pages
iPSC derived NK cells - Pipeline Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “IPSCs derived NK cells – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 30+ pipe...
March 2022
60 pages
Malignant Pleural Mesothelioma- Pipeline Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 48-72 hours DelveInsight’s, “Malignant Pleural Mesothelioma- Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies an...
March 2022
60 pages
Metastatic Colorectal cancer - Pipeline Insight, 2022
US$ 5,000.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “Metastatic Colorectal cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 140+ companies and 1...
March 2022
200 pages
Natural Killer (NK) cell therapy - Pipeline Insight, 2022
US$ 5,000.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “Natural Killer (NK) cell therapy – Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies a...
March 2022
200 pages
Sezary Syndrome - Pipeline Insghts, 2022
US$ 1,250.00
This report can be delivered to the clients within 72 hours DelveInsight’s, “Sezary syndrome – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drug...
March 2022
40 pages
Type2 Diabetes Mellitus- Pipeline Insight, 2022
US$ 3,000.00
This report can be delivered to the clients within 72 Hours DelveInsight’s, “Type2 Diabetes Mellitus- Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pi...
March 2022
100 pages
Abilify - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Abilify API intelligence over Abilify and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Acne vulgaris - Epidemiology Forecast to 2032
US$ 3,950.00
... 7MM with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Acne vulgaris Key assessments Patient Segmentation in Acne vulgaris Acne vulgaris Risk & Burden Factors driving growth in a specific Acne vulgaris patient population
January 2022
60 pages
Acne Vulgaris - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Pipeline Analysis Acne Vulgaris (AV) Market Size and Trends Acne Vulgaris (AV) Market Opportunities Impact of upcoming Therapies in Acne Vulgaris (AV) Acne Vulgaris (AV) Report Key Strengths 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Acne ...
January 2022
200 pages
Actinic Keratosis - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Keratosis Pipeline Analysis Actinic Keratosis Market Size and Trends Actinic Keratosis Market Opportunities Impact of upcoming Therapies in Actinic Keratosis Actinic Keratosis Report Key Strengths 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition ...
January 2022
200 pages
Adderall - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Adderall API intelligence over Adderall and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
alimta - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Alimta API intelligence over Alimta and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Alopecia - Epidemiology Forecast to 2032
US$ 3,950.00
... 7MM with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Alopecia Key assessments Patient Segmentation in Alopecia Alopecia Risk & Burden Factors driving growth in a specific Alopecia patient population
January 2022
60 pages
Ambisome - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Ambisome API intelligence over Ambisome and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Amitiza - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Amitiza API intelligence over Amitiza and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Asthma - Epidemiology Forecast to 2032
US$ 3,950.00
... 7MM with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Asthma Key assessments Patient Segmentation in Asthma Asthma Risk & Burden Factors driving growth in a specific Asthma patient population
January 2022
60 pages
Atripla - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Atripla API intelligence over Atripla and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Baraklyud - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Baraklyud API intelligence over Baraklyud and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Bepanthene - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Bepanthene API intelligence over Bepanthene and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Caduet - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Caduet API intelligence over Caduet and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Candidiasis - Epidemiology Forecast to 2032
US$ 3,950.00
... 7MM with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Candidiasis Key assessments Patient Segmentation in Candidiasis Candidiasis Risk & Burden Factors driving growth in a specific Candidiasis patient population
January 2022
60 pages
Cansidas - API Insight, 2022
US$ 500.00
... patent expiry details with respect to Cansidas API intelligence over Cansidas and gaining primary intelligence over Active Ingredient manufacturers by country Make more informed business decisions from insightful ...
January 2022
30 pages
Chemotherapy Induced Nausea and Vomiting - Epidemiology Forecast to 2032
US$ 3,950.00
... Forecast 7MM Coverage Total Cases in Chemotherapy Induced Nausea and Vomiting Key assessments Patient Segmentation in Chemotherapy Induced Nausea and Vomiting Chemotherapy Induced Nausea and Vomiting Risk & Burden Factors driving growth in a specific Chemotherapy Induced Nausea and Vomiting patient population ...
January 2022
60 pages